Plasma exosome-derived fragile-site associated tumor suppressor is a powerful predictor of prognosis in patients with ovarian cancer
Open Access
- 7 September 2021
- journal article
- research article
- Published by Association of Basic Medical Sciences of FBIH in Bosnian Journal of Basic Medical Sciences
- Vol. 22 (3), 453-459
- https://doi.org/10.17305/bjbms.2021.6404
Abstract
The objective of the study was to investigate the levels of plasma exosome-derived fragile site-associated tumor suppressor (FATS) and evaluate its prognostic predictive ability in ovarian cancer (OC) patients. Exosome-rich fractions were isolated from the plasma of 90 patients with OC enrolled in this study. The levels of plasma exosome-derived FATS were detected by ELISA. The levels of exosome-derived FATS in OC patients were significantly lower as compared to the healthy controls (P < 0.001). The levels of plasma exosome-derived FATS were higher in OC patients with low grade (1/2), and Federation International of Gynecology and Obstetrics (FIGO) Stages I/II than those in high grade (3/4) and Stages III/IV of the disease (p = 0.003; p < 0.001), respectively. The levels of plasma exosome-derived FATS were significantly higher in OC patients with no lymph node metastasis or no ascites as compared to those with lymph node metastasis or ascites, respectively (both p < 0.001). The levels of plasma exosome-derived FATS were higher in OC patients having CA-125 below 35 U/ml as compared to those with CA-125 greater than 35 U/ml (p < 0.001). Among all enrolled OC patients, both 5-DFS and 5-OS were shorter in patients with lower plasma exosome-derived FATS levels than those with higher levels (both p < 0.001). The area under the receiver operating characteristic curve of plasma exosome-derived FATS was 0.85 (95% CI: 0.76-0.91) for 5-DFS and 0.91 (95% CI: 0.83-0.96) for 5-OS prediction in patients with OC. Plasma exosome-derived FATS levels in OC patients were significantly downregulated. Low levels of plasma exosome-derived FATS had a significant relationship with FIGO Stages III/IV, high grade, ascites, higher levels of CA-125, lymph node metastasis, and prognosis of OC patients. Thus, our findings may provide insights for the development of a new strategy OC treatment.Keywords
Funding Information
- Young Medical Key Talents Foundation of Jiangsu Province (QNRC2016163)
This publication has 25 references indexed in Scilit:
- Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulationBiomedicine & Pharmacotherapy, 2019
- Decoding the Biology of Exosomes in MetastasisTrends in Cancer, 2019
- Radiation-Induced Chromosomal Breaks may be DNA Repair Fragile Sites with Larger-scale Correlations to Eight Double-Strand-Break Related Data Sets over the Human GenomeRadiation Research, 2019
- Proteomic characterization of chromosomal common fragile site (CFS)-associated proteins uncovers ATRX as a regulator of CFS stabilityNucleic Acids Research, 2019
- Clinical significance of high expression of stanniocalcin-2 in hepatocellular carcinomaBioscience Reports, 2019
- BLM prevents instability of structure-forming DNA sequences at common fragile sitesPLoS Genetics, 2018
- The value of FATS expression in predicting sensitivity to radiotherapy in breast cancerOncotarget, 2017
- A functional genetic variant in fragile-site gene FATS modulates the risk of breast cancer in triparous womenBMC Cancer, 2015
- Common Fragile Sites: Genomic Hotspots of DNA Damage and CarcinogenesisInternational Journal of Molecular Sciences, 2012
- Expression level of novel tumor suppressor gene FATS is associated with the outcome of node positive breast cancer2011